Welcome to the 3rd Spatial Biology for Drug Development Summit!
This year's forum unites key players from AbbVie, AstraZeneca, Amgen, Genentech, Daiichi Sankyo, Johnson & Johnson, and more, to catalyze the discovery and development of more effective therapeutics across numerous disease areas.
This is your opportunity to gain actionable insights and takeaways across 2-days to take a deep dive into spatial biology case studies across the entire drug discovery and development chain.
Full pricing and registration details for our *FREE to attend passes, eligibility criteria and more are available within the brochure.
*Having trouble downloading the brochure?
Let us know and we’ll email it to you instead.
Session Spotlight:
Conference Day One
9:00 AM
Boosting Reproducibility & Standardization to Drive Real-World Spatial Biology Adoption
Details:
- Overcoming the practical challenges of generating reproducible spatial data across sites, timepoints, and platforms, and why this is crucial for real translational impact
- Aligning workflows and performance criteria to build confidence in spatial assays, from tissue handling to image analysis and interpretation
- Accelerating the journey from pilot projects to everyday adoption by addressing the bottlenecks that hold back scalable, deployable biomarkers in pharma pipelines
Companies on the Program:
Hear From Your Peers:
“The value of this meeting lies in the focused, cross-sector discussions that drive new ideas, challenge assumptions, and connect science to real-world needs. It’s a chance to engage directly with thought leaders, stay current, and help shape the direction of the field.”
Director - Mental Health, Neuroscience, FNIH